Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Role of TKIs in Nonadipocytic Soft Tissue Sarcoma and Advanced Osteosarcoma

Source: Current Topics in Oncology
In this podcast episode, Jean-Yves Blay, MD, PhD, and Robin L. Jones, BSc, MBBS, MRCP, MD(Res), discuss key data on using TKIs as monotherapy and in combination with chemotherapy or immune checkpoint inhibitors for treatment of soft tissue sarcoma and osteosarcoma.
person default
Jean Yves Blay, MD, PhD
Robin L. Jones, BSc, MBBS, MRCP, MD(Res)
Released: November 2, 2021

In this podcast episode, Jean-Yves Blay, MD, PhD, and Robin L. Jones, BSc, MBBS, MRCP, MD(Res), discuss the most important clinical trial data on leveraging TKIs as monotherapy and in combination with chemotherapy or immune checkpoint inhibitors for treatment of soft tissue sarcoma and osteosarcoma.

Information on this Educational Activity

Faculty

Jean Yves Blay, MD, PhD

Professor of Medical Oncology
Department of Medicine
Centre Leon Berard
Lyon, France

Jean Yves Blay, MD, PhD, has disclosed that he has received funds for research support and consulting fees from Bayer, Blueprint, Deciphera, Novartis, PharmaMar, and Roche.
Robin L. Jones, BSc, MBBS, MRCP, MD(Res)

Professor
Sarcoma Unit
Royal Marsden Hospital and Institute of Cancer Research
London, United Kingdom

Robin L. Jones, BSc, MBBS, MRCP, MD(Res), has disclosed that he has received consulting fees from Adaptimmune, Astex, Athenex, Bayer, Boehringer Ingelheim, Blueprint, Clinigen, Daichii, Deciphera, Eisai, Epizyme, Immunedesign, Immunicum, Karma Oncology, Lilly, Merck, Mundipharma, PharmaMar, Spring Works, SynOx, and Tracon.

Program Medium

This program has been made available online.

Acknowledgements

Supported by an educational grant from
Bayer HealthCare Pharmaceuticals Inc.

Related Content

Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered malignancies.

Alexander Drilon, MD
Program Director Thomas Stinchcombe, MD
Program Director Released: August 4, 2022

Gain expert insight on managing NTRK- and RET-altered malignancies and optimal methods for detecting gene fusions, in this webcast from Clinical Care Options (CCO)

Alexander Drilon, MD
Program Director Thomas Stinchcombe, MD
Program Director person default Saad A. Khan, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: June 10, 2022 Expired: June 9, 2023

Dr. Robin L. Jones offers expert commentary on TKI therapy in advanced osteosarcoma and nonadipocytic sarcoma, from Clinical Care Options (CCO)

Robin L. Jones, BSc, MBBS, MRCP, MD(Res) Released: May 25, 2022

Clinical Care Options (CCO): Joshua Sabari, MD, provides insights into the emerging targeted therapies for patients with NRG1-positive solid tumors

Joshua Sabari, MD Released: February 28, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings